CRISPR-Functionalized Lipid Nanoparticles for Precision Eradication of Multidrug-Resistant Bacterial Pathogens
Abstract
The global escalation of multidrug-resistant (MDR) bacterial infections necessitates the development of highly specific antimicrobial strategies. CRISPR-Cas systems enable programmable gene targeting, while lipid nanoparticles (LNPs) provide efficient intracellular delivery of nucleic acids. In this study, we engineered CRISPR-functionalized lipid nanoparticles (CRISPR-LNPs) for targeted disruption of key antibiotic resistance genes in MDR Escherichia coli and Staphylococcus aureus. Cas9–sgRNA ribonucleoprotein complexes were encapsulated using microfluidic nanoprecipitation. The nanoparticles were characterized for size, charge, morphology, and encapsulation efficiency. Antibacterial efficacy, biofilm disruption, and mammalian cytotoxicity were systematically evaluated. CRISPR-LNPs exhibited optimal nanoscale size (~100 nm), high encapsulation efficiency (>90%), and significant bacterial killing (>4 log reduction). Biofilm biomass decreased by up to 80%, while mammalian cell viability remained above 90%. These findings demonstrate that CRISPR-LNPs represent a promising precision antimicrobial platform against MDR pathogens and support further translational development.
How to Cite
Shalini Saini, "CRISPR-Functionalized Lipid Nanoparticles for Precision Eradication of Multidrug-Resistant Bacterial Pathogens", Vol. 3, Issue 1, 21-01-2026, pp. 88-95.
